Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Erratum: HLA-DRA Class II Molecule as a Marker for Immuno-Active Tumors and Its Role in Predicting Response to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer

  • By

  • Jie Mei

  • Guanyu Jiang

  • Yundi Chen

  • Yongrui Xu

  • Yuan Wan

  • Ruo Chen

  • Feng Liu

  • Wenjun Mao

  • Mingfeng Zheng

  • Junying Xu

  • September 17, 2026

Share

Clinical Report: Erratum on HLA-DRA as a Marker in NSCLC

Background

HLA-DRA is a class II molecule that may serve as a biomarker for immuno-active tumors, particularly in NSCLC. Understanding its role in predicting responses to therapies like anti-PD-1 is crucial for this patient population.

Data Highlights

No numerical or trial data is presented in the erratum.

Key Findings

  • The original article contained an error in the representation of Figure 5E.
  • The PR HLA-DRA and PR PD-L1 panels were inadvertently duplicated.
  • The correction does not alter the study’s conclusions regarding HLA-DRA.

Clinical Implications

The correction emphasizes the need for careful review of published data.

Conclusion

The erratum clarifies a data representation issue without affecting the original study's conclusions on HLA-DRA's role in NSCLC.

Related Resources & Content

  1. BMC Cancer, 2022 -- Erratum: HLA-DRA Class II Molecule as a Marker for Immuno-Active Tumors
  2. Frontiers in Immunology — HLA-G Expression in Non-Small Cell Lung Cancer: prognostic significance and interplay with PD-L1 and CD8+ Tumor-Infiltrating Lymphocytes
  3. JAMA Oncology — Errors in Figures
  4. Bone Marrow Transplantation — Amendment to: Efficacy of PD1 Inhibitor Combined with 5-Azacytidine and Low-Dose DLI in Treating AML Patients Post-Transplant Relapse
  5. Frontiers in Immunology — HHLA2 as an emerging immune checkpoint in lung cancer: linking EGFR signaling, macrophage polarization, and CD8+ T-cell metabolic suppression
  6. Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0
  7. Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation - PubMed
  8. HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC - PMC

Original Source(s)

Correction to: HLA Class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

  • by Jie Mei, Guanyu Jiang, Yundi Chen, Yongrui Xu, Yuan Wan, Ruo Chen, Feng Liu, Wenjun Mao, Mingfeng Zheng, Junying Xu

  • September 17, 2026

Related Content

Retraction Note: TWIST1 activates cancer stem cell marker genes to promote epithelial‑mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma

Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge

Personalized Cancer Vaccine Linked to Three-Year Disease-Free Survival in Head and Neck Cancer

All 16 patients who received TG4050 after standard treatment remained disease-free, compared with 13 of 16 patients in the control group

  • September 16, 2026

  • 2 min